MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma
The ENS@T consortium received funding from the European Union Seventh Framework Programme (ENS@T-CANCER; HEALTH F2-2010259735). The ENS@T registry is supported by a grant of the European Science Foundation (ESF-ENS@T). This work was supported in part by the Fondo de Investigaciones Sanitarias (projects PI11/01359, PS09/00942, PI10/01290, PI08/0531 and P108/0883), Mutua Madrileña (AP2775/2008), Consejería de Innovacion Ciencia y Empresa de la Junta de Andalucía (CTS-2590), Red Tematica de Investigacion Cooperativa en Cancer (RD06/0020/0034). The French COMETE network is supported in part by the Programme HospitalierdeRechercheCliniquegrantCOMETE3(AOM0619),bygrants from INSERM and Ministere Deleguea la Recherche et des Nouvelles Technologies and by the Institut National du Cancer. This work was also funded by grants from the Agence Nationale de la Recherche (ANR 08 GENOPATH 029 MitOxy) and by the national program "Cartes d’Identite des Tumeurs" funded and developed by the "Ligue Nationale contre le Cancer" (http://cit.ligue cancer.net). This research was supported, in part, by the Intramural Research Program of the NIH, NICHD. This work received funding support from the Voelcker Fund to P.L.M. Dahia. This work was also supported in part by grantsfrom the Fondazione Comunita Bresciana and the Fondazione Guido Berlucchi. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Fondo de Investigaciones Sanitarias/PI11/01359
Fondo de Investigaciones Sanitarias/PS09/00942
- Artículos